2 Scopus citations

Abstract

Research on the use of plants for production of protein-based therapeutics has increased tremendously since the initial experiments in the early 1990s. Plant-based expression systems offer several production advantages of low cost, rapidity, scalability, and a significantly lower chance of contamination with prion or mammalian viruses. In addition, the capability of plants in producing homogeneous N-glycans allows the development of novel therapeutics with superior efficacy and safety to their mammalian cell-produced counterparts. Various plant species have been used to develop and produce vaccines, antibodies, and pharmaceutical enzymes against a myriad of diseases by multiple expression technologies. While most of these plant-made therapeutics are in preclinical development, many have progressed into human clinical study phases and several have been approved by regulatory agencies. The current status and recent advancement of plant-based expression systems and key clinical products will be presented in this chapter. The remaining challenges and future directions for the field of plant-made therapeutics will be discussed.

Original languageEnglish (US)
Title of host publicationTransgenic Plants
PublisherAcademic Press Inc
Pages207-244
Number of pages38
DOIs
StatePublished - Jan 1 2018

Publication series

NameAdvances in Botanical Research
Volume86
ISSN (Print)0065-2296

    Fingerprint

Keywords

  • Flavivirus
  • Monoclonal antibody
  • Nicotiana benthamiana
  • Plant expression system
  • Plant-made biologics
  • Plant-made pharmaceutical
  • Therapeutic enzymes
  • Transient expression
  • Vaccine
  • Virus-like particle

ASJC Scopus subject areas

  • Plant Science

Cite this

Chen, Q. (2018). Recombinant Therapeutic Molecules Produced in Plants. In Transgenic Plants (pp. 207-244). (Advances in Botanical Research; Vol. 86). Academic Press Inc. https://doi.org/10.1016/bs.abr.2017.11.006